[The clinical pharmacokinetics of allopurinol. 1. Allopurinol absorption sites and dose proportionality of allopurinol/oxipurinol bioavailability]. 1985

O Schuster, and M Haertel, and B Hugemann, and I Gikalov, and O Schiemann, and H Fenner

The rate and extent of allopurinol absorption was studied following its oral ingestion in a "high frequency capsule" which allows the evaluation of the sites of drug absorption. If allopurinol is liberated in the duodenum or upper jejunum its absorption is fast and complete while its liberation in the lower jejunum results in a slow and incomplete absorption. A capacity limited absorption process for allopurinol, suggested from the results of a study on the allopurinol bioavailability from different formulations, could not be proved in the range of single doses between 200 and 600 mg resp. 2.2 to 12.8 mg/kg. AUC- and Cp-values of allopurinol and oxipurinol correspond to the calculated figures in relation to the different doses/kg.

UI MeSH Term Description Entries
D007408 Intestinal Absorption Uptake of substances through the lining of the INTESTINES. Absorption, Intestinal
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D010117 Oxypurinol A xanthine oxidase inhibitor. Alloxanthine,Oxipurinol
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000493 Allopurinol A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms. Allohexal,Allohexan,Alloprin,Allopurin,Allorin,Allpargin,Allural,Apulonga,Apurin,Atisuril,Bleminol,Caplenal,Capurate,Cellidrin,Embarin,Foligan,Hamarin,Jenapurinol,Lopurin,Lysuron,Milurit,Milurite,Novopurol,Pan Quimica,Progout,Pureduct,Purinol,Remid,Rimapurinol,Roucol,Suspendol,Tipuric,Uribenz,Uridocid,Uripurinol,Urosin,Urtias,Xanthomax,Xanturic,Zygout,Zyloprim,Zyloric
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

O Schuster, and M Haertel, and B Hugemann, and I Gikalov, and O Schiemann, and H Fenner
June 1986, Arzneimittel-Forschung,
O Schuster, and M Haertel, and B Hugemann, and I Gikalov, and O Schiemann, and H Fenner
September 2017, Clinical therapeutics,
O Schuster, and M Haertel, and B Hugemann, and I Gikalov, and O Schiemann, and H Fenner
January 1992, Journal of pharmaceutical sciences,
O Schuster, and M Haertel, and B Hugemann, and I Gikalov, and O Schiemann, and H Fenner
March 2016, Pulmonary circulation,
O Schuster, and M Haertel, and B Hugemann, and I Gikalov, and O Schiemann, and H Fenner
January 1989, British journal of clinical pharmacology,
O Schuster, and M Haertel, and B Hugemann, and I Gikalov, and O Schiemann, and H Fenner
September 1987, Journal of clinical pharmacology,
O Schuster, and M Haertel, and B Hugemann, and I Gikalov, and O Schiemann, and H Fenner
January 1986, Advances in experimental medicine and biology,
O Schuster, and M Haertel, and B Hugemann, and I Gikalov, and O Schiemann, and H Fenner
July 2010, Current drug metabolism,
O Schuster, and M Haertel, and B Hugemann, and I Gikalov, and O Schiemann, and H Fenner
July 2011, Journal of clinical pharmacology,
O Schuster, and M Haertel, and B Hugemann, and I Gikalov, and O Schiemann, and H Fenner
June 2016, Journal of ethnopharmacology,
Copied contents to your clipboard!